These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16098255)

  • 1. Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors.
    Fakih M; Cao S; Durrani FA; Rustum YM
    Clin Colorectal Cancer; 2005 Jul; 5(2):132-5. PubMed ID: 16098255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
    Cao S; Durrani FA; Rustum YM
    Clin Cancer Res; 2004 Apr; 10(7):2561-9. PubMed ID: 15073137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
    Bhattacharya A; Tóth K; Durrani FA; Cao S; Slocum HK; Chintala S; Rustum YM
    Neoplasia; 2008 Aug; 10(8):857-65. PubMed ID: 18670644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.
    Azrak RG; Cao S; Pendyala L; Durrani FA; Fakih M; Combs GF; Prey J; Smith PF; Rustum YM
    Biochem Pharmacol; 2007 May; 73(9):1280-7. PubMed ID: 17239826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis.
    Yin MB; Li ZR; Tóth K; Cao S; Durrani FA; Hapke G; Bhattacharya A; Azrak RG; Frank C; Rustum YM
    Oncogene; 2006 Apr; 25(17):2509-19. PubMed ID: 16518418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
    Chintala S; Tóth K; Cao S; Durrani FA; Vaughan MM; Jensen RL; Rustum YM
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):899-911. PubMed ID: 20066420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation.
    Azrak RG; Cao S; Durrani FA; Toth K; Bhattacharya A; Rustum YM
    Cancer Lett; 2011 Dec; 311(2):219-29. PubMed ID: 21872389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.
    Azrak RG; Yu J; Pendyala L; Smith PF; Cao S; Li X; Shannon WD; Durrani FA; McLeod HL; Rustum YM
    Mol Cancer Ther; 2005 May; 4(5):843-54. PubMed ID: 15897249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models.
    Cao S; Durrani FA; Tóth K; Rustum YM
    Br J Cancer; 2014 Apr; 110(7):1733-43. PubMed ID: 24619073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs.
    Bhattacharya A; Seshadri M; Oven SD; Tóth K; Vaughan MM; Rustum YM
    Clin Cancer Res; 2008 Jun; 14(12):3926-32. PubMed ID: 18559614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs.
    Bhattacharya A
    Expert Opin Drug Deliv; 2011 Jun; 8(6):749-63. PubMed ID: 21473705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumor activity of capecitabine in combination with irinotecan.
    Cao S; Durrani FA; Rustum YM
    Clin Colorectal Cancer; 2005 Jan; 4(5):336-43. PubMed ID: 15663838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis.
    Li Z; Carrier L; Belame A; Thiyagarajah A; Salvo VA; Burow ME; Rowan BG
    Breast Cancer Res Treat; 2009 Nov; 118(1):33-43. PubMed ID: 18855134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.
    Fakih MG; Pendyala L; Smith PF; Creaven PJ; Reid ME; Badmaev V; Azrak RG; Prey JD; Lawrence D; Rustum YM
    Clin Cancer Res; 2006 Feb; 12(4):1237-44. PubMed ID: 16489079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors.
    Fakih MG; Pendyala L; Brady W; Smith PF; Ross ME; Creaven PJ; Badmaev V; Prey JD; Rustum YM
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):499-508. PubMed ID: 17989978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteopontin is a potential target gene in mouse mammary cancer chemoprevention by Se-methylselenocysteine.
    Unni E; Kittrell FS; Singh U; Sinha R
    Breast Cancer Res; 2004; 6(5):R586-92. PubMed ID: 15318939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy.
    Rustum YM; Chintala S; Durrani FA; Bhattacharya A
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30380599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles.
    Gao F; Yuan Q; Gao L; Cai P; Zhu H; Liu R; Wang Y; Wei Y; Huang G; Liang J; Gao X
    Biomaterials; 2014 Oct; 35(31):8854-8866. PubMed ID: 25064805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of blocking agents and suppressing agents in cancer prevention.
    Ip C; Ganther HE
    Carcinogenesis; 1991 Feb; 12(2):365-7. PubMed ID: 1899813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Se-methylselenocysteine sensitized TRAIL-mediated apoptosis via down-regulation of Bcl-2 expression.
    Lee JT; Lee TJ; Park JW; Kwon TK
    Int J Oncol; 2009 May; 34(5):1455-60. PubMed ID: 19360359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.